Table 3

Differences in renal function during therapy
Parameter Voriconazole Caspofungin Fluconazole
Baseline Clcr (mL/min) <30 30–50 p-value <30 30–50 p-value <30 30–50 p-value
n (%) 6 (31.6) 13 (68.4) -- 33 (60.0) 22 (40.0) -- 27 (50.0) 27 (50.0) --
Maximum ↑ Scr, mg/dL (SD) 0.68 (1.01) 0.62 (0.54) 0.88 1.17 (1.9) 0.15 (0.78) 0.02 2.6 (2.7) 2.0 (2.0) 0.33
Lowest Clcr during treatment, mL/min (SD) 16.8 (3.7) 31.7 (7.3) 0.0002 15.8 (6.0) 34.6 (7.7) <0.0001 13.9 (5.1) 24.3(8.2) <0.0001
Clcr at EOT, mL/min (SD) 28.7 (18.1) 50.3(27.8) 0.11 46.4(43.1) 59.5(28.4) 0.21 30.6(19.2) 49.0(22.6) 0.0025
% Change Clcr (Lowest-SOT)/SOT (SD) −24.6 (12.6) −19.6 (13.4) 0.45 −19.4(17.7) −15.6(15.1) 0.41 −35.3(18.4) −37.5(20.7) 0.68
Renal dysfunction, n (%) 3 (50.0) 4 (30.8) 0.42 12 (36.4) 3 (13.6) 0.06 17 (63.0) 15 (55.6) 0.58

Scr: serum creatinine; Clcr: creatinine clearance; EOT: end of therapy, SOT: start of therapy.

Lilly et al.

Lilly et al. BMC Infectious Diseases 2013 13:14   doi:10.1186/1471-2334-13-14

Open Data